JNCE News and Press, Jounce Therapeutics Inc. From 03/30/21

Today, we peek back in on Jounce Therapeutics for the first time in nearly two years. It seems a good time to revisit this small developmental firm as the company has advanced its pipeline and addressed its current funding needs. A full analysis on Jounce is provided in the paragr...

CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the closing of its previously announced underwritten pu...

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that preclinical data informing indication selecti...

Jounce Therapeutics (JNCE) has priced its public offering of 5M common shares at $11.25/share, for gross proceeds of ~$56.25M. Underwriters' over-allotment is an additional 750K shares.The proceeds are expected to be used to fund ongoing and planned clinical trials, to fund R&D to advance...

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has priced an underwritten public offering of 5...

Jounce Therapeutics (JNCE) trades 7% down afterhours after announcing that it is offering to sell shares in an underwritten public offering.Underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer proceeds are expected to be used for funding on...

CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it is offering to sell shares of its common stock ...

Two new breakout stocks for Week 10 of 2021 with better than 10% short-term upside potential. This past week both LMAT +12.5% and YI +12.2% gained more than 10% while the average return to the close for all four tech/healthcare selections was a loss of -22.9%. 2021 MDA portfolio r...

Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Conference Call February 25, 2021 08:00 ET Company Participants Malin Deon - Investor Relations Rich Murray - President & Chief Executive Officer Elizabeth Trehu - Chief Medical Officer Kim Drapkin - Chief Financial Officer Conference Call...

Image source: The Motley Fool. Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q4 2020 Earnings Call Feb 26, 2021 , 8:00 p.m. ET Operator Continue reading For further details see: Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call Transcript...